The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges
The use of particles to develop vaccines and treatments for a wide variety of diseases has increased, and their success has been demonstrated in preclinical investigations. Accurately targeting cells and minimizing doses and adverse side effects, while inducing an adequate biological response, are i...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/11/8/1988 |
| _version_ | 1797583789161971712 |
|---|---|
| author | Alejandra Barrera-Rosales Romina Rodríguez-Sanoja Rogelio Hernández-Pando Silvia Moreno-Mendieta |
| author_facet | Alejandra Barrera-Rosales Romina Rodríguez-Sanoja Rogelio Hernández-Pando Silvia Moreno-Mendieta |
| author_sort | Alejandra Barrera-Rosales |
| collection | DOAJ |
| description | The use of particles to develop vaccines and treatments for a wide variety of diseases has increased, and their success has been demonstrated in preclinical investigations. Accurately targeting cells and minimizing doses and adverse side effects, while inducing an adequate biological response, are important advantages that particulate systems offer. The most used particulate systems are liposomes and their derivatives, immunostimulatory complexes, virus-like particles, and organic or inorganic nano- and microparticles. Most of these systems have been proven using therapeutic or prophylactic approaches to control tuberculosis, one of the most important infectious diseases worldwide. This article reviews the progress and current state of the use of particles for the administration of TB vaccines and treatments in vitro and in vivo, with a special emphasis on polymeric particles. In addition, we discuss the challenges and benefits of using these particulate systems to provide researchers with an overview of the most promising strategies in current preclinical trials, offering a perspective on their progress to clinical trials. |
| first_indexed | 2024-03-10T23:43:00Z |
| format | Article |
| id | doaj.art-c321d395b50645ed8f8bd1ed9c28bac0 |
| institution | Directory Open Access Journal |
| issn | 2076-2607 |
| language | English |
| last_indexed | 2024-03-10T23:43:00Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj.art-c321d395b50645ed8f8bd1ed9c28bac02023-11-19T02:17:18ZengMDPI AGMicroorganisms2076-26072023-08-01118198810.3390/microorganisms11081988The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and ChallengesAlejandra Barrera-Rosales0Romina Rodríguez-Sanoja1Rogelio Hernández-Pando2Silvia Moreno-Mendieta3Posgrado en Ciencias Bioquímicas, Universidad Nacional Autónoma de México (UNAM), A.P. 70228, Ciudad Universitaria, Ciudad de México 04510, MéxicoInstituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), A.P. 70228, Ciudad Universitaria, Ciudad de México 04510, MéxicoSección de Patología Experimental, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Delegación Tlalpan, Ciudad de México 14080, MéxicoInstituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), A.P. 70228, Ciudad Universitaria, Ciudad de México 04510, MéxicoThe use of particles to develop vaccines and treatments for a wide variety of diseases has increased, and their success has been demonstrated in preclinical investigations. Accurately targeting cells and minimizing doses and adverse side effects, while inducing an adequate biological response, are important advantages that particulate systems offer. The most used particulate systems are liposomes and their derivatives, immunostimulatory complexes, virus-like particles, and organic or inorganic nano- and microparticles. Most of these systems have been proven using therapeutic or prophylactic approaches to control tuberculosis, one of the most important infectious diseases worldwide. This article reviews the progress and current state of the use of particles for the administration of TB vaccines and treatments in vitro and in vivo, with a special emphasis on polymeric particles. In addition, we discuss the challenges and benefits of using these particulate systems to provide researchers with an overview of the most promising strategies in current preclinical trials, offering a perspective on their progress to clinical trials.https://www.mdpi.com/2076-2607/11/8/1988polymeric nano- and microparticlesdelivery systemstuberculosis prophylaxistuberculosis treatment |
| spellingShingle | Alejandra Barrera-Rosales Romina Rodríguez-Sanoja Rogelio Hernández-Pando Silvia Moreno-Mendieta The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges Microorganisms polymeric nano- and microparticles delivery systems tuberculosis prophylaxis tuberculosis treatment |
| title | The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges |
| title_full | The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges |
| title_fullStr | The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges |
| title_full_unstemmed | The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges |
| title_short | The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges |
| title_sort | use of particulate systems for tuberculosis prophylaxis and treatment opportunities and challenges |
| topic | polymeric nano- and microparticles delivery systems tuberculosis prophylaxis tuberculosis treatment |
| url | https://www.mdpi.com/2076-2607/11/8/1988 |
| work_keys_str_mv | AT alejandrabarrerarosales theuseofparticulatesystemsfortuberculosisprophylaxisandtreatmentopportunitiesandchallenges AT rominarodriguezsanoja theuseofparticulatesystemsfortuberculosisprophylaxisandtreatmentopportunitiesandchallenges AT rogeliohernandezpando theuseofparticulatesystemsfortuberculosisprophylaxisandtreatmentopportunitiesandchallenges AT silviamorenomendieta theuseofparticulatesystemsfortuberculosisprophylaxisandtreatmentopportunitiesandchallenges AT alejandrabarrerarosales useofparticulatesystemsfortuberculosisprophylaxisandtreatmentopportunitiesandchallenges AT rominarodriguezsanoja useofparticulatesystemsfortuberculosisprophylaxisandtreatmentopportunitiesandchallenges AT rogeliohernandezpando useofparticulatesystemsfortuberculosisprophylaxisandtreatmentopportunitiesandchallenges AT silviamorenomendieta useofparticulatesystemsfortuberculosisprophylaxisandtreatmentopportunitiesandchallenges |